Volume 67, Issue 3, Pages (March 2015)

Slides:

Advertisements

Similar presentations

Combination chemotherapy with bevacizumab and S-1 for elderly patients with metastatic colorectal cancer (BASIC trial) M. Yoshida, K. Muro, A. Tsuji,

Advertisements

Volume 50, Issue 1, Pages (July 2006)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 58, Issue 2, Pages (August 2010)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

Table 1 Baseline patient characteristics

Volume 70, Issue 6, Pages (December 2016)

Volume 60, Issue 2, Pages (August 2011)

EAU Guidelines on Testicular Cancer: 2011 Update

Let the Games Begin (with EAU Approval)

Ashish M. Kamat, Sima Porten European Urology

Volume 72, Issue 5, Pages (November 2017)

Volume 51, Issue 5, Pages (May 2007)

Prostate Cancer Epidemic in Sight?

Volume 52, Issue 4, Pages (October 2007)

Volume 63, Issue 1, Pages (January 2013)

Daily Administration of Phosphodiesterase Type 5 Inhibitors for Urological and Nonurological Indications Anthony J. Bella, Ling X. DeYoung, Mussa al-Numi,

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Volume 52, Issue 1, Pages (July 2007)

Volume 66, Issue 2, Pages (August 2014)

Volume 74, Issue 1, Pages (July 2018)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 73, Issue 2, Pages (February 2018)

Volume 61, Issue 4, Pages (April 2012)

Volume 67, Issue 3, Pages (March 2015)

Volume 64, Issue 5, Pages (November 2013)

Volume 69, Issue 3, Pages (March 2016)

Volume 64, Issue 3, Pages (September 2013)

Volume 67, Issue 3, Pages (March 2015)

Volume 53, Issue 2, Pages (February 2008)

Volume 64, Issue 4, Pages (October 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 53, Issue 6, Pages (June 2008)

Volume 66, Issue 2, Pages (August 2014)

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Lisa M. Brown, MD, MAS, David T. Cooke, MD, Elizabeth A. David, MD

Volume 50, Issue 5, Pages (November 2006)

Anna Grenabo Bergdahl, Erik Holmberg, Sue Moss, Jonas Hugosson

Patient-reported symptoms and performance status before palliative radiotherapy in geriatric cancer patients (octogenarians) Carsten Nieder, Thomas A.

Volume 52, Issue 6, Pages (December 2007)

Volume 55, Issue 6, Pages (June 2009)

Volume 71, Issue 5, Pages (May 2017)

Volume 67, Issue 6, Pages (June 2015)

Testicular Cancer Variations in Time and Space in Europe

Volume 49, Issue 4, Pages (April 2006)

Maurizio Brausi, Federica Rizzi, Saverio Bettuzzi European Urology

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Prognostic Impact of Comorbidity in Patients with Bladder Cancer

Volume 70, Issue 1, Pages (July 2016)

Volume 385, Issue 9962, Pages (January 2015)

European Urology is “Your” Journal

Volume 74, Issue 6, Pages (December 2018)

A Phase II Study of Paclitaxel + Etoposide + Cisplatin + Concurrent Radiation Therapy for Previously Untreated Limited Stage Small Cell Lung Cancer (E2596):

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Volume 16, Issue 8, Pages (August 2015)

Volume 373, Issue 9658, Pages (January 2009)

Standard versus Dose-Intensified Chemotherapy with Sequential Reinfusion of Hematopoietic Progenitor Cells in Small Cell Lung Cancer Patients with Favorable.

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

European Association of Urology Guidelines for Systemic Therapy in Metastatic Renal Cell Carcinoma: What is Recommended and Why? Jean-Jacques Patard

Volume 371, Issue 9618, Pages (March 2008)

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Volume 52, Issue 1, Pages (July 2007)

James D Luketich, Michael E Burt The Annals of Thoracic Surgery

Volume 67, Issue 4, Pages (April 2015)

Penile and Testicular Cancer: What's New in 2006?

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 67, Issue 3, Pages 534-543 (March 2015) A Randomised Phase 2 Trial of Intensive Induction Chemotherapy (CBOP/BEP) and Standard BEP in Poor-prognosis Germ Cell Tumours (MRC TE23, CRUK 05/014, ISRCTN 53643604) Robert A. Huddart, Rhian Gabe, Fay H. Cafferty, Philip Pollock, Jeff D. White, Jonathan Shamash, Michael H. Cullen, Sally P. Stenning European Urology Volume 67, Issue 3, Pages 534-543 (March 2015) DOI: 10.1016/j.eururo.2014.06.034 Copyright © 2015 The Authors Terms and Conditions

Fig. 1 Chemotherapy regimens. AUC=area under the curve; BEP=bleomycin, etoposide, and cisplatin; CBOP/BEP=carboplatin, bleomycin, vincristine, cisplatin/bleomycin, etoposide, and cisplatin. # Etoposide to be given at 100mg/m2 daily over 5 d. § Cisplatin to be given at 20mg/m2 daily for 5 d. £ Cisplatin to be given at 50mg/m2 days 1 and 2 or 20mg/m2 daily for 5 d (weeks 1 and 3). ¢ Bleomycin to be given at 15 000 IU by 24-h infusion daily over 5 d. European Urology 2015 67, 534-543DOI: (10.1016/j.eururo.2014.06.034) Copyright © 2015 The Authors Terms and Conditions

Fig. 2 Trial profile. BEP=bleomycin, etoposide, and cisplatin; CBOP/BEP=carboplatin, bleomycin, vincristine, cisplatin/bleomycin, etoposide, and cisplatin; GCT=germ cell tumour; IGCCCG=International Germ Cell Cancer Collaborative Group. European Urology 2015 67, 534-543DOI: (10.1016/j.eururo.2014.06.034) Copyright © 2015 The Authors Terms and Conditions

Fig. 3 Kaplan-Meier plots for (A) progression-free survival and (B) overall survival. BEP=bleomycin, etoposide, and cisplatin; CBOP/BEP=carboplatin, bleomycin, vincristine, cisplatin/bleomycin, etoposide, and cisplatin. European Urology 2015 67, 534-543DOI: (10.1016/j.eururo.2014.06.034) Copyright © 2015 The Authors Terms and Conditions